The Complement System in Lupus Nephritis

Seminars in Nephrology

Volumn 35, Issue 5, 2015, Pages 444-454

  Birmingham, Daniel J ^a   Hebert, Lee A ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Complement; Lupus nephritis

Indexed keywords

BIOLOGICAL MARKER; COMPLEMENT; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3D; COMPLEMENT COMPONENT C4; COMPLEMENT COMPONENT C5A; COMPLEMENT MEMBRANE ATTACK COMPLEX; ECULIZUMAB; IMMUNOGLOBULIN;

ANTIGEN ANTIBODY COMPLEX; ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT CLASSICAL PATHWAY; COMPLEMENT SYSTEM; DRUG TARGETING; HUMAN; IMMUNOPATHOGENESIS; IMMUNOREGULATION; KIDNEY INJURY; LUPUS ERYTHEMATOSUS NEPHRITIS; PRIORITY JOURNAL; PROTEIN FUNCTION; IMMUNOLOGY; SYSTEMIC LUPUS ERYTHEMATOSUS;

COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM PROTEINS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS;

EID: 84961614135     PISSN: 02709295     EISSN: 15584488     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2015.08.006     Document Type: Review

References (91)

1. Walport M.J. Complement. First of two parts. N Engl J Med 2001, 344:1058-1066.
2. Walport M.J. Complement. Second of two parts. N Engl J Med 2001, 344:1140-1144.
3. Matsushita M., Endo Y., Fujita T. Structural and functional overview of the lectin complement pathway: its molecular basis and physiological implication. Arch Immunol Ther Exp (Warsz) 2013, 61:273-283.
4. Holers V.M. Complement and its receptors: new insights into human disease. Annu Rev Immunol 2014, 32:433-459.
5. Zipfel P.F., Skerka C. Complement regulators and inhibitory proteins. Nat Rev Immunol 2009, 9:729-740.
6. Hourcade D.E., Holers V.M., Atkinson J.P. The regulators of complement activation (RCA) gene cluster. Adv Immunol 1989, 45:381-416.
7. Markiewski M.M., Lambris J.D. The role of complement in inflammatory diseases from behind the scenes into the spotlight. Am J Pathol 2007, 171:715-727.
8. Holers V.M., Kulik L. Complement receptor 2, natural antibodies and innate immunity: inter-relationships in B cell selection and activation. Mol Immunol 2007, 44:64-72.
9. Asokan R., Banda N.K., Szakonyi G., Chen X.S., Holers V.M. Human complement receptor 2 (CR2/CD21) as a receptor for DNA: implications for its roles in the immune response and the pathogenesis of systemic lupus erythematosus (SLE). Mol Immunol 2013, 53:99-110.
10. Strainic M.G., Liu J., Huang D., An F., Lalli P.N., Muqim N., et al. Locally produced complement fragments C5a and C3a provide both costimulatory and survival signals to naive CD4+ T cells. Immunity 2008, 28:425-435.
11. Strainic M.G., Shevach E.M., An F., Lin F., Medof M.E. Absence of signaling into CD4(+) cells via C3aR and C5aR enables autoinductive TGF-beta1 signaling and induction of Foxp3(+) regulatory T cells. Nat Immunol 2013, 14:162-171.
12. Birmingham D.J., Hebert L.A. CR1 and CR1-like: the primate immune adherence receptors. Immunol Rev 2001, 180:100-111.
13. Cornacoff J.B., Hebert L.A., Smead W.L., VanAman M.E., Birmingham D.J., Waxman F.J. Primate erythrocyte-immune complex-clearing mechanism. J Clin Invest 1983, 71:236-247.
14. Truedsson L., Bengtsson A.A., Sturfelt G. Complement deficiencies and systemic lupus erythematosus. Autoimmunity 2007, 40:560-566.
15. Stegert M., Bock M., Trendelenburg M. Clinical presentation of human C1q deficiency: how much of a lupus?. Mol Immunol 2015, 67:3-11.
16. Pickering M.C., Botto M., Taylor P.R., Lachmann P.J., Walport M.J. Systemic lupus erythematosus, complement deficiency, and apoptosis. Adv Immunol 2000, 76:227-324.
17. Hebert L., Cosio F., Birmingham D., Sedmak D. Circulating immune complexes. Immunochemistry 1994, 653-680. Marcel Dekker, New York. C. van Oss, M.H.V. van Regenmortel (Eds.).
18. Hebert L.A., Birmingham D.J., Shen X.P., Cosio F.G., Fryczkowski A. Rate of antigen entry into the circulation in experimental versus naturally occurring immune complex glomerulonephritis. J Am Soc Nephrol 1994, 5(Suppl 1):S70-S75.
19. Hebert L., Cosio F., Birmingham D. Complement and complement regulatory proteins. Immunologic renal diseases 2001, 367-393. Lippincott Williams & Williams, Philadelphia. 2nd ed. E. Neilson, W. Couser (Eds.).
20. Schifferli J.A., Steiger G., Hauptmann G., Spaeth P.J., Sjoholm A.G. Formation of soluble immune complexes by complement in sera of patients with various hypocomplementemic states. Difference between inhibition of immune precipitation and solubilization. J Clin Invest 1985, 76:2127-2133.
21. Sanchez-Cuenca J.M. Complement mediated solubilization: role of the complement in the clearance of circulating immune-complexes. Allergol Immunopathol (Madr) 1994, 22:197-203.
22. Waxman F.J., Hebert L.A., Cornacoff J.B., VanAman M.E., Smead W.L., Kraut E.H., et al. Complement depletion accelerates the clearance of immune complexes from the circulation of primates. J Clin Invest 1984, 74:1329-1340.
23. Waxman F.J., Hebert L.A., Cosio F.G., Smead W.L., VanAman M.E., Taguiam J.M., et al. Differential binding of immunoglobulin A and immunoglobulin G1 immune complexes to primate erythrocytes in vivo. Immunoglobulin A immune complexes bind less well to erythrocytes and are preferentially deposited in glomeruli. J Clin Invest 1986, 77:82-89.
24. Davies K.A., Hird V., Stewart S., Sivolapenko G.B., Jose P., Epenetos A.A., et al. A study of in vivo immune complex formation and clearance in man. J Immunol 1990, 144:4613-4620.
25. Schifferli J.A., Ng Y.C., Estreicher J., Walport M.J. The clearance of tetanus toxoid/anti-tetanus toxoid immune complexes from the circulation of humans. Complement- and erythrocyte complement receptor 1-dependent mechanisms. J Immunol 1988, 140:899-904.
26. Davies K.A., Peters A.M., Beynon H.L., Walport M.J. Immune complex processing in patients with systemic lupus erythematosus. In vivo imaging and clearance studies. J Clin Invest 1992, 90:2075-2083.
27. Kim-Howard X., Maiti A.K., Anaya J.M., Bruner G.R., Brown E., Merrill J.T., et al. ITGAM coding variant (rs1143679) influences the risk of renal disease, discoid rash, and immunologic manifestations in lupus patients with European ancestry. Ann Rheum Dis 2010, 69:1329-1332.
28. Toller-Kawahisa J.E., Vigato-Ferreira I.C., Pancoto J.A., Mendes-Junior C.T., Martinez E.Z., Palomino G.M., et al. The variant of CD11b, rs1143679 within ITGAM, is associated with systemic lupus erythematosus and clinical manifestations in Brazilian patients. Hum Immunol 2014, 75:119-123.
29. Rhodes B., Furnrohr B.G., Roberts A.L., Tzircotis G., Schett G., Spector T.D., et al. The rs1143679 (R77H) lupus associated variant of ITGAM (CD11b) impairs complement receptor 3 mediated functions in human monocytes. Ann Rheum Dis 2012, 71:2028-2034.
30. Birmingham D.J., Irshaid F., Nagaraja H.N., Zou X., Tsao B.P., Wu H., et al. The complex nature of serum C3 and C4 as biomarkers of lupus renal flare. Lupus 2010, 19:1272-1280.
31. Watanabe H., Garnier G., Circolo A., Wetsel R.A., Ruiz P., Holers V.M., et al. Modulation of renal disease in MRL/lpr mice genetically deficient in the alternative complement pathway factor B. J Immunol 2000, 164:786-794.
32. Elliott M.K., Jarmi T., Ruiz P., Xu Y., Holers V.M., Gilkeson G.S. Effects of complement factor D deficiency on the renal disease of MRL/lpr mice. Kidney Int 2004, 65:129-138.
33. Su W., Madaio M.P. Recent advances in the pathogenesis of lupus nephritis: autoantibodies and B cells. Semin Nephrol 2003, 23:564-568.
34. Seredkina N., Van Der Vlag J., Berden J., Mortensen E., Rekvig O.P. Lupus nephritis: enigmas, conflicting models and an emerging concept. Mol Med 2013, 19:161-169.
35. Schmiedeke T.M., Stockl F.W., Weber R., Sugisaki Y., Batsford S.R., Vogt A. Histones have high affinity for the glomerular basement membrane. Relevance for immune complex formation in lupus nephritis. J Exp Med 1989, 169:1879-1894.
36. Kalaaji M., Fenton K.A., Mortensen E.S., Olsen R., Sturfelt G., Alm P., et al. Glomerular apoptotic nucleosomes are central target structures for nephritogenic antibodies in human SLE nephritis. Kidney Int 2007, 71:664-672.
37. Yin Y., Wu X., Shan G., Zhang X. Diagnostic value of serum anti-C1q antibodies in patients with lupus nephritis: a meta-analysis. Lupus 2012, 21:1088-1097.
38. Mannik M., Wener M.H. Deposition of antibodies to the collagen-like region of C1q in renal glomeruli of patients with proliferative lupus glomerulonephritis. Arthritis Rheum 1997, 40:1504-1511.
39. Trouw L.A., Groeneveld T.W., Seelen M.A., Duijs J.M., Bajema I.M., Prins F.A., et al. Anti-C1q autoantibodies deposit in glomeruli but are only pathogenic in combination with glomerular C1q-containing immune complexes. J Clin Invest 2004, 114:679-688.
40. Prada A.E., Strife C.F. IgG subclass restriction of autoantibody to solid-phase C1q in membranoproliferative and lupus glomerulonephritis. Clin Immunol Immunopathol 1992, 63:84-88.
41. Haseley L.A., Wisnieski J.J., Denburg M.R., Michael G.A., Ginzler E.M., Gourley M.F., et al. Antibodies to C1q in systemic lupus erythematosus: characteristics and relation to FcgammaRIIA alleles. Kidney Int 1997, 52:1375-1380.
42. Wallace D.J., Hahn B.H., Klippel J.H. Lupus nephritis. Dubois' lupus erythematosus 1997, 1053-1065. Williams and Wilkins, Baltimore. D.J. Wallace, B.H. Hahn (Eds.).
43. Cameron J.S. Lupus nephritis. J Am Soc Nephrol 1999, 10:413-424.
44. Ricker D.M., Hebert L.A., Rohde R., Sedmak D.D., Lewis E.J., Clough J.D. Serum C3 levels are diagnostically more sensitive and specific for systemic lupus erythematosus activity than are serum C4 levels. The Lupus Nephritis Collaborative Study Group. Am J Kidney Dis 1991, 18:678-685.
45. Esdaile J.M., Abrahamowicz M., Joseph L., MacKenzie T., Li Y., Danoff D. Laboratory tests as predictors of disease exacerbations in systemic lupus erythematosus. Why some tests fail. Arthritis Rheum 1996, 39:370-378.
46. Sullivan K.E., Wisnieski J.J., Winkelstein J.A., Louie J., Sachs E., Choi R., et al. Serum complement determinations in patients with quiescent systemic lupus erythematosus. J Rheumatol 1996, 23:2063-2067.
47. Yang Y., Chung E.K., Zhou B., Lhotta K., Hebert L.A., Birmingham D.J., et al. The intricate role of complement component C4 in human systemic lupus erythematosus. Curr Dir Autoimmun 2004, 7:98-132.
48. Sturfelt G., Johnson U., Sjoholm A.G. Sequential studies of complement activation in systemic lupus erythematosus. Scand J Rheumatol 1985, 14:184-196.
49. Buyon J.P., Tamerius J., Belmont H.M., Abramson S.B. Assessment of disease activity and impending flare in patients with systemic lupus erythematosus. Comparison of the use of complement split products and conventional measurements of complement. Arthritis Rheum 1992, 35:1028-1037.
50. D'Agati VD, Stokes MB. Renal disease in systemic lupus erythematsus, mixed connective tissue disease, sjogren's syndrome, and rheumatoid arthritis. In: Jeannette JC, Olson JL, Schwartz MM, Silva FG, eds. Heptinstall's Pathology of the Kidney. 7th ed. Philadelphia, PA: Wolters Kluwer; 2014:517-612.
51. Falk R.J., Dalmasso A.P., Kim Y., Lam S., Michael A. Radioimmunoassay of the attack complex of complement in serum from patients with systemic lupus erythematosus. N Engl J Med 1985, 312:1594-1599.
52. Belmont H.M., Hopkins P., Edelson H.S., Kaplan H.B., Ludewig R., Weissmann G., et al. Complement activation during systemic lupus erythematosus. C3a and C5a anaphylatoxins circulate during exacerbations of disease. Arthritis Rheum 1986, 29:1085-1089.
53. Stohl W., Hiepe F., Latinis K.M., Thomas M., Scheinberg M.A., Clarke A., et al. Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. Arthritis Rheum 2012, 64:2328-2337.
54. Wild G., Watkins J., Ward A.M., Hughes P., Hume A., Rowell N.R. C4a anaphylatoxin levels as an indicator of disease activity in systemic lupus erythematosus. Clin Exp Immunol 1990, 80:167-170.
55. Manzi S., Rairie J.E., Carpenter A.B., Kelly R.H., Jagarlapudi S.P., Sereika S.M., et al. Sensitivity and specificity of plasma and urine complement split products as indicators of lupus disease activity. Arthritis Rheum 1996, 39:1178-1188.
56. Nagy G., Brozik M., Varga L., Fust G., Kirschfink M., Kiss E., et al. Usefulness of detection of complement activation products in evaluating SLE activity. Lupus 2000, 9:19-25.
57. Manzi S., Navratil J.S., Ruffing M.J., Liu C.C., Danchenko N., Nilson S.E., et al. Measurement of erythrocyte C4d and complement receptor 1 in systemic lupus erythematosus. Arthritis Rheum 2004, 50:3596-3604.
58. Liu C.C., Manzi S., Kao A.H., Navratil J.S., Ruffing M.J., Ahearn J.M. Reticulocytes bearing C4d as biomarkers of disease activity for systemic lupus erythematosus. Arthritis Rheum 2005, 52:3087-3099.
59. Navratil J.S., Manzi S., Kao A.H., Krishnaswami S., Liu C.C., Ruffing M.J., et al. Platelet C4d is highly specific for systemic lupus erythematosus. Arthritis Rheum 2006, 54:670-674.
60. Birmingham DJ. Type one complement receptor and human SLE. In: Kammer GM, Tsokos GC, eds. Lupus: Molecular and Cellular Pathogenesis. Totowa, NJ: Humana Press; 1999:541-556.
61. Birmingham D.J., Hebert L.A., Cosio F.G., VanAman M.E. Immune complex erythrocyte complement receptor interactions in vivo during induction of glomerulonephritis in nonhuman primates. J Lab Clin Med 1990, 116:242-252.
62. Birmingham D.J., Gavit K.F., McCarty S.M., Yu C.Y., Rovin B.H., Nagaraja H.N., et al. Consumption of erythrocyte CR1 (CD35) is associated with protection against systemic lupus erythematosus renal flare. Clin Exp Immunol 2006, 143:274-280.
63. Melhorn M.I., Brodsky A.S., Estanislau J., Khoory J.A., Illigens B., Hamachi I., et al. CR1-mediated ATP release by human red blood cells promotes CR1 clustering and modulates the immune transfer process. J Biol Chem 2013, 288:31139-31153.
64. Antes U., Heinz H.P., Loos M. Evidence for the presence of autoantibodies to the collagen-like portion of C1q in systemic lupus erythematosus. Arthritis Rheum 1988, 31:457-464.
65. Walport M.J., Davies K.A., Botto M., Naughton M.A., Isenberg D.A., Biasi D., et al. C3 nephritic factor and SLE: report of four cases and review of the literature. QJM 1994, 87:609-615.
66. Kusunoki Y., Akutsu Y., Itami N., Tochimaru H., Nagata Y., Takekoshi Y., et al. Urinary excretion of terminal complement complexes in glomerular disease. Nephron 1991, 59:27-32.
67. Kelly R.H., Carpenter A.B., Sudol K.S., Jagarlapudi S.P., Manzi S. Complement C3 fragments in urine: detection in systemic lupus erythematosus patients by Western blotting. Appl Theor Electrophor 1993, 3:265-269.
68. Negi V.S., Aggarwal A., Dayal R., Naik S., Misra R. Complement degradation product C3d in urine: marker of lupus nephritis. J Rheumatol 2000, 27:380-383.
69. Gou S.J., Yuan J., Wang C., Zhao M.H., Chen M. Alternative complement pathway activation products in urine and kidneys of patients with ANCA-associated GN. Clin J Am Soc Nephrol 2013, 8:1884-1891.
70. Satoskar A.A., Brodsky S.V., Nadasdy G., Bott C., Rovin B., Hebert L., et al. Discrepancies in glomerular and tubulointerstitial/vascular immune complex IgG subclasses in lupus nephritis. Lupus 2011, 20:1396-1403.
71. Appel GB, Jayne D, Rovin BH. Lupus Nephritis. In: Johnson RJ, Feehally J, Floege J, eds. Comprehensive Clinical Nephrology. 5th ed. Philadelphia, PA: Elsevier Inc; 2015:303-316.
72. Emancipator S.N., Iida K., Nussenzweig V., Gallo G.R. Monoclonal antibodies to human complement receptor (CR1) detect defects in glomerular diseases. Clin Immunol Immunopathol 1983, 27:170-175.
73. Kazatchkine M.D., Fearon D.T., Appay M.D., Mandet C., Bariety J. Immunohistochemical study of the human glomerular C3b receptor in normal kidney and in seventy five cases of renal diseases. J Clin Invest 1982, 69:900-912.
74. Cosio F.G., Sedmak D.D., Mahan J.D., Nahman N.S. Localization of decay accelerating factor in normal and diseased kidneys. Kidney Int 1989, 36:100-107.
75. Endoh M., Yamashina M., Ohi H., Funahashi K., Ikuno T., Yasugi T., et al. Immunohistochemical demonstration of membrane cofactor protein (MCP) of complement in normal and diseased kidney tissues. Clin Exp Immunol 1993, 94:182-188.
76. Korbet S.M., Lewis E.J., Schwartz M.M., Reichlin M., Evans J., Rohde R.D. Factors predictive of outcome in severe lupus nephritis. Lupus Nephritis Collaborative Study Group. Am J Kidney Dis 2000, 35:904-914.
77. Schaier M., Scholl C., Scharpf D., Hug F., Bonisch-Schmidt S., Dikow R., et al. Proton pump inhibitors interfere with the immunosuppressive potency of mycophenolate mofetil. Rheumatology (Oxford) 2010, 49:2061-2067.
78. Hebert L.A., Rovin B.H. Oral cyclophosphamide is on the verge of extinction as therapy for severe autoimmune diseases (especially lupus): should nephrologists care?. Nephron Clin Pract 2011, 117. c8-14.
79. Rinder C.S., Rinder H.M., Smith B.R., Fitch J.C., Smith M.J., Tracey J.B., et al. Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation. J Clin Invest 1995, 96:1564-1572.
80. Thomas T.C., Rollins S.A., Rother R.P., Giannoni M.A., Hartman S.L., Elliott E.A., et al. Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv. Mol Immunol 1996, 33:1389-1401.
81. Burwick R.M., Burwick N.R., Feinberg B.B. Eculizumab fails to inhibit generation of C5a in vivo. Blood 2014, 124:3502-3503.
82. Hillmen P., Young N.S., Schubert J., Brodsky R.A., Socie G., Muus P., et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 2006, 355:1233-1243.
83. Schmidtko J., Peine S., El-Housseini Y., Pascual M., Meier P. Treatment of atypical hemolytic uremic syndrome and thrombotic microangiopathies: a focus on eculizumab. Am J Kidney Dis 2013, 61:289-299.
84. Coppo R., Peruzzi L., Amore A., Martino S., Vergano L., Lastauka I., et al. Dramatic effects of eculizumab in a child with diffuse proliferative lupus nephritis resistant to conventional therapy. Pediatr Nephrol 2015, 30:167-172.
85. El-Husseini A., Hannan S., Awad A., Jennings S., Cornea V., Sawaya B.P. Thrombotic microangiopathy in systemic lupus erythematosus: efficacy of eculizumab. Am J Kidney Dis 2015, 65:127-130.
86. Erkan D., Aguiar C.L., Andrade D., Cohen H., Cuadrado M.J., Danowski A., et al. 14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends. Autoimmun Rev 2014, 13:685-696.
87. Wenderfer S.E., Thacker T. Intravenous immunoglobulin in the management of lupus nephritis. Autoimmune Dis 2012, 2012:589359.
88. Asghar S.S., Pasch M.C. Therapeutic inhibition of the complement system. Y2K update. Front Biosci 2000, 5:E63-82A.
89. Ricklin D., Lambris J.D. Complement in immune and inflammatory disorders: therapeutic interventions. J Immunol 2013, 190:3839-3847.
90. Hebert L.A., Birmingham D.J., Shen X.P., Cosio F.G. Stimulating erythropoiesis increases complement receptor expression on primate erythrocytes. Clin Immunol Immunopathol 1992, 62:301-306.
91. Hebert L.A., Birmingham D.J., Dillon J.J., Cosio F.G., Shen X.P. Erythropoietin therapy in humans increases erythrocyte expression of complement receptor type 1 (CD35). J Am Soc Nephrol 1994, 4:1786-1791.